Skip to content

therapeutic role of repititive transcranial magnetic stimulation in patients with Fibromyalgia

ROLE OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN TREATMENT OF PATIENT OF FIBROMYALGIA: A RANDOMIZED CONTROLLED TRAIL - rTMS, Fibromyalgia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/051395
Enrollment
45
Registered
2023-04-10
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M797- Fibromyalgia

Interventions

Intervention1: High frequency repetitive Transcranial Magnetic resonance: high frequencyrTMS will be given on patients of fibromyalgia with pretaken consent and several parameters will be compared bef

Sponsors

Department of Neurology MLB Medical College, Jhansi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study will be conducted on patients attending at the department of neurology and psychiatry , MLB MC, Jhansi India and diagnosed as fibromyalgia as per ACR guideline 2010.

Exclusion criteria

Exclusion criteria: FMS patients will be excluded from the study, if they had following conditions: i) unable to give written informed consent form ii) History of seizures iii) History of seizures in first-degree relatives iv) History of any illness involving the brain v) Consumption of medications (like tramadol, acetylcholinesterase inhibitors, anticholinergics, antiemetics,antihistamines, baclofen, Ã?-blockers, cephalosporins,cyclosporine etc) known to lower the seizure threshold vi) History of tinnitus vii) History of bipolar disorder viii) having implants of defibrillators or neurostimulators or cardiac pacemakers ix) pregnant or lactating x) having chronic systemic disease, inflammatory joint diseases, secondary FM, history of trauma xi) with a concomitant diagnosis of chronic fatigue syndrome and/or any psychiatric disorder xii) currently undergoing psychotherapy.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be defined as a reduction in pain intensity. This will be assessed with the help of Numerical Pain Rating Scale (NPRS), an 11-point numerical scale ranging from â??0â?? representing â??No painâ?? to â??10â?? representing â??Pain as bad as you can imagineâ?? or â??Worst pain imaginableâ??Timepoint: at the end of the intervention then at 1 month and 3 month of end of interention

Secondary

MeasureTime frame
Pain related depression, anxiety, impact of pain and quality of life, as secondary outcomes will be assessed using FIQR ; Hamilton Depression Rating Scale (HDRS); Hamilton Anxiety Rating Scale (HARS) questionnaire .Timepoint: at the end of the intervention then at 1 month and 3 month of end of interention

Countries

India

Contacts

Public ContactDr Arvind Kankane

Maharani Laxmibai Medical College

drarvind_neuro@rediffmail.com9838072655

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026